Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Acquired Diseases
  • Published:

In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells

Gene Therapy volume 7, pages 1738–1743 (2000)Cite this article

Abstract

This report examines a major barrier to suicide gene therapy in cancer and other diseases: namely, bystander cell killing. Existing vectors for in vivo gene delivery are inefficient and often transduce or transfect less than 1% of target cells. The E. coli PNP gene brings about cellular necrosis under conditions when 1 in 100 to 1 in 1000 cells express the gene product in vitro. In vivo bystander killing at or near this magnitude has not been reported previously. In the present experiments, transfection of cells with the E. coli PNP gene controlled by a SV40 promoter resulted in 30 nmol 6-methyl purine deoxyriboside (MeP-dR) converted per milligram tumor cell extract per hour (or conversion units (CU)). This level of expression led to elimination of entire populations of tumor cells in vitro after treatment with MeP-dR. Much earlier killing was observed using a tat transactivated E. coli PNP vector (approximately seven-fold higher activity, 230 CU). In vivo effects on tumor growth were next examined. Human ovarian tumors transfected with E. coli PNP were excised 5 days after i.p. implantation from the peritoneal cavities of mice in order to determine both E. coli PNP enzymatic activity and the fraction of cells expressing the gene. PNP activity at 5 days after gene transfer was approximately 170 CU and was expressed in approximately 0.1% of the tumor cells as judged by in situ hybridization. The expression of E. coli PNP at this level produced a 30% increase in life span (P < 0.001) and 49% reduction in tumor size (P < 0.005) after MeP-dR treatment, as compared with control tumors. Our observations lead to the conclusion that pronounced bystander killing by E. coli PNP is conferred in vivo, and that vectors capable of transgene expression in as few as one in 1000 cells can produce substantial antitumor effects if expression on a per cell basis is very high.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Sorscher EJ et al. Tumor cell bystander killing in colonic carcinoma utilizing the E. coli Deo D gene to generate toxic purines Gene Therapy 1994 1: 233–238

    CAS  PubMed  Google Scholar 

  2. Hughes BW et al. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene Cancer Res 1995 55: 3339–3345

    CAS  PubMed  Google Scholar 

  3. Da Costa LT et al. Converting cancer genes into killer genes Proc Natl Acad Sci USA 1996 93: 4192–4196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Parker WB et al. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase Hum Gene Ther 1997 8: 1637–1644

    Article  CAS  PubMed  Google Scholar 

  5. Hughes BW et al. Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase J Biol Chem 1998 273: 2322–2328

    Article  CAS  PubMed  Google Scholar 

  6. Parker WB et al. Metabolism and metabolic action of 6-methylpurine and 2-fluoroadenine in human cells Biochem Pharm 1998 55: 1673–1681

    Article  CAS  PubMed  Google Scholar 

  7. Lockett LJ, Molloy PL, Russell PJ, Both GW . Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors Clin Cancer Res 1997 3: 2075–2080

    CAS  PubMed  Google Scholar 

  8. Martiniello-Wilks R et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors Hum Gene Ther 1998 9: 1617–1626

    Article  CAS  PubMed  Google Scholar 

  9. Puhlmann M et al. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy Hum Gene Ther 1999 10: 649–657

    Article  CAS  PubMed  Google Scholar 

  10. Jensen KF, Nygaard P . Purine nucleoside phosphorylase from Escherichia coli and Salmonella typhimurium. Purification and some properties Eur J Biochem 1975 51: 253–265

    Article  CAS  PubMed  Google Scholar 

  11. Mao C et al. The crystal structure of Escherichia coli purine nucleoside phosphorylase: a comparison with the human enzyme reveals a conserved topology Structure 1997 5: 1373–1383

    Article  CAS  PubMed  Google Scholar 

  12. Nestler U et al. Foamy virus vectors for suicide gene therapy Gene Therapy 1997 4: 1270–1277

    Article  CAS  PubMed  Google Scholar 

  13. Niculescu-Duvaz I, Spooner R, Marais R, Springer CJ . Gene-directed enzyme prodrug therapy Bioconjug Chem 1998 9: 4–22

    Article  CAS  PubMed  Google Scholar 

  14. Hoganson DK, Batra RK, Olsen JC, Boucher RC . Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma Cancer Res 1996 56: 1315–1323

    CAS  PubMed  Google Scholar 

  15. Beck C et al. The thymidine kinase/ganciclovir-mediated ‘suicide’ effect is variable in different tumor cells Hum Gene Ther 1995 6: 1525–1530

    Article  CAS  PubMed  Google Scholar 

  16. Dilber MS et al. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo Cancer Res 1997 57: 1523–1528

    CAS  PubMed  Google Scholar 

  17. Elshami AA et al. Gap junctions play a role in the ‘bystander effect’ of the herpes simplex virus thymidine kinase/ganciclovir system in vitro Gene Therapy 1996 3: 85–92

    CAS  PubMed  Google Scholar 

  18. Fick J et al. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro Proc Natl Acad Sci USA 1995 92: 11071–11055

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Imaizumi K et al. Bystander tumoricidal effect gap junctional communication in lung cancer cell lines Am J Respir Cell Mol Biol 1998 18: 205–212

    Article  CAS  PubMed  Google Scholar 

  20. Freeman SM et al. The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified Cancer Res 1993 53: 5274–5283

    CAS  PubMed  Google Scholar 

  21. Sacco MG et al. Partial regression, yet incomplete eradication of mammary tumors in transgenic mice by retrovirally mediated HSVtk transfer in vivo Gene Therapy 1996 3: 1151–1156.

    CAS  PubMed  Google Scholar 

  22. Marini FCr, Nelson JA, Lapeyre JN . Assessment of bystander effect potency produced by intratumoral implantation of HSVtk-expressing cells using surrogate marker secretion to monitor tumor growth kinetics Gene Therapy 1995 2: 655–659

    CAS  PubMed  Google Scholar 

  23. Vile RG et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component Cancer Res 1994 54: 6228–6234

    CAS  PubMed  Google Scholar 

  24. Caruso M et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma Proc Natl Acad Sci USA 1996 93: 11302–11306

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Tapscott SJ et al. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection Proc Natl Acad Sci USA 1994 91: 8185–8189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Huber BE et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase Proc Natl Acad Sci USA 1994 91: 8302–8306

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physiology and Biophysics, University of Alabama at Birmingham, USA

    V K Gadi, S D Alexander, J E Kudlow & E J Sorscher

  2. Department of Medicine, University of Alabama at Birmingham, USA

    J E Kudlow & E J Sorscher

  3. Southern Research Institute, Birmingham, AL, USA

    P Allan & W B Parker

Authors
  1. V K Gadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S D Alexander
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J E Kudlow
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P Allan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W B Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E J Sorscher
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gadi, V., Alexander, S., Kudlow, J. et al. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells. Gene Ther 7, 1738–1743 (2000). https://doi.org/10.1038/sj.gt.3301286

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3301286

Keywords

This article is cited by

Search

Advanced search

Quick links